Throughout this AJMC Peer Exchange®, a panel of experts in infectious disease and managed care will discuss today’s management of HIV, including the need for individualized care and the role for newer treatment options.
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More